What is semaglutide?

What is a GLP-1 receptor agonist?

Semaglutide belongs to a class of prescription medicines called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a hormone the small intestine naturally releases after a meal. Drugs in this class are synthetic molecules engineered to bind to and activate the same receptors that natural GLP-1 does, reproducing its effects but lasting far longer in the bloodstream. Native GLP-1 breaks down within roughly two minutes; the chemical structure of semaglutide extends its activity to approximately seven days, making once-weekly injectable dosing practical. GLP-1 receptors are found throughout the body, including in the pancreas, brain, stomach, heart, and kidneys. This wide distribution explains why GLP-1 receptor agonists affect blood sugar, appetite, body weight, and cardiovascular health simultaneously rather than through a single pathway. Semaglutide's insulin-stimulating effect is glucose-dependent, meaning it triggers insulin release primarily when blood glucose is elevated. This design makes dangerously low blood sugar (hypoglycemia) uncommon in people without diabetes who take the drug. Other approved GLP-1 receptor agonists include liraglutide and dulaglutide. Tirzepatide is a related but distinct drug that also targets a second receptor called GIP; for a side-by-side comparison of these two options, see Semaglutide vs tirzepatide: what is the difference?

How was semaglutide discovered and developed?

Semaglutide emerged from decades of incretin research at Novo Nordisk, the Danish pharmaceutical company that had earlier brought the daily GLP-1 receptor agonist liraglutide to market. Scientists designing semaglutide needed to solve two practical problems: the rapid destruction of GLP-1 by an enzyme called DPP-IV, and the inconvenience of daily injections. Their solution involved two targeted modifications to the natural GLP-1 molecule. First, they substituted the amino acid at position 8 (replacing alanine with aminoisobutyric acid), protecting the molecule against DPP-IV degradation while preserving its ability to activate the GLP-1 receptor. Second, they attached a C18 fatty acid chain through a specialized linker, allowing the molecule to bind loosely to albumin, a protein abundant in blood. The albumin-bound fraction circulates without being cleared, while the small free fraction activates receptors in tissues. These modifications produced a half-life of approximately seven days, as documented in a review in Frontiers in Endocrinology (2019). Novo Nordisk ran phase 3 SUSTAIN trials for the injectable diabetes formulation, and the FDA granted its first semaglutide approval on December 5, 2017. An oral diabetes formulation followed in September 2019, and a higher-dose injectable specifically for weight management received approval in June 2021, marking the first time semaglutide was formally indicated for obesity.

How does semaglutide work in the body?

Semaglutide produces its effects by activating GLP-1 receptors in at least three key locations. In the pancreas, it tells beta cells to release insulin when blood glucose is high and suppresses glucagon, the hormone that signals the liver to release stored glucose. In the gut, it slows gastric emptying, meaning food takes longer to leave the stomach, extending the feeling of fullness after a meal. This gastric-emptying effect tends to ease with continued use through a process called tachyphylaxis, while appetite-reducing effects generally persist, according to a review published in the Journal of Nuclear Medicine Technology. In the brain, GLP-1 receptors concentrated in the hypothalamus and brainstem register semaglutide as a satiety signal, reducing hunger and often quieting what many patients describe as constant preoccupation with food. These central effects appear to be responsible for most of the weight loss observed in clinical trials. Semaglutide also seems to have direct protective effects on the cardiovascular system that go beyond what weight reduction alone would predict, though the precise cardiac mechanisms remain an active area of research. After starting once-weekly injections, the drug reaches steady-state concentrations in the blood after approximately four to five weeks, which is why the full appetite-suppressing effect builds gradually and dose-titration schedules typically span several months.

What conditions is semaglutide FDA-approved to treat?

The FDA has approved semaglutide for three distinct clinical purposes, depending on the brand and dose. The first is improving blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise. Both injectable and oral formulations carry this indication. The second is chronic weight management in adults with obesity (body mass index of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnea. The higher-dose injectable Wegovy also carries an FDA approval for adolescents aged 12 and older with obesity, as noted in StatPearls. The third indication covers cardiovascular risk reduction in adults with established heart disease who also have obesity or overweight, regardless of whether they have diabetes. This approval came in March 2024 following the SELECT trial. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (a specific type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2 (MEN2). Starting or stopping any prescription medicine should only happen under the guidance of a licensed clinician who has reviewed a patient's full medical history.

What forms and brands does semaglutide come in?

Semaglutide is available under four FDA-approved brand names covering both injectable and oral routes. The table below summarizes each product's form, dosing, and primary approved use.

The oral Wegovy pill, approved on December 22, 2025, was the first oral GLP-1 receptor agonist approved for weight management in adults. It uses a tablet technology that improves semaglutide absorption enough to achieve therapeutic blood levels without an injection. Rybelsus, the earlier oral form, is approved only for type 2 diabetes at its lower dose range and is not interchangeable with oral Wegovy. All four products require a valid prescription from a licensed provider.

What do clinical trials show about semaglutide for weight loss?

The most influential evidence for semaglutide as a weight management medicine comes from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity and no type 2 diabetes received either injectable Wegovy (semaglutide 2.4 mg weekly) or placebo alongside lifestyle counseling. At 68 weeks, participants in the semaglutide group lost an average of 14.9% of body weight, compared with 2.4% in the placebo group. These results belong specifically to FDA-approved injectable Wegovy (semaglutide 2.4 mg) studied under controlled trial conditions with lifestyle support. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials; individual outcomes depend on dose, adherence, medical history, and lifestyle. For the oral form, the OASIS 4 trial (NEJM, 2025) reported a mean 16.6% weight loss with 25 mg oral Wegovy among those who adhered to treatment. These two results are not directly comparable: they come from separate trials with different routes of administration, doses, populations, and analysis sets (intention-to-treat versus per-protocol). Cross-trial comparisons cannot be used to determine whether one form produces better outcomes than the other. These results apply to FDA-approved oral Wegovy and not to compounded semaglutide, which is not FDA-approved and has not been evaluated in equivalent clinical trials; individual outcomes vary based on dose, adherence, medical history, and lifestyle. Both injectable and oral forms are intended to be used alongside a reduced-calorie eating pattern and increased physical activity. Food choices during treatment matter considerably for tolerability and outcomes; What should you eat while taking semaglutide? covers the evidence on dietary approaches. For realistic expectations about the timeline to see changes, see How fast does semaglutide work?

What did the SELECT trial show about semaglutide and heart health?

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial enrolled 17,604 adults with established cardiovascular disease, a BMI of 27 or higher, and no type 2 diabetes. Participants were randomly assigned to receive injectable Wegovy (semaglutide 2.4 mg weekly) or placebo and were followed for up to five years. The trial found that semaglutide reduced the risk of major adverse cardiovascular events, defined as nonfatal heart attack, nonfatal stroke, or cardiovascular death, by 20 percent compared with placebo. On March 8, 2024, the FDA used these findings to expand Wegovy's label to include cardiovascular risk reduction, making it the first treatment specifically approved for that purpose in adults with overweight or obesity and pre-existing heart disease. Researchers noted that the cardiovascular benefit appeared to exceed what weight loss alone would explain, suggesting the drug may have direct cardioprotective effects, though the mechanisms are still being studied. These findings apply to FDA-approved injectable Wegovy at the studied dose and formulation. Anyone with existing cardiovascular disease should work closely with a cardiologist or primary care provider to determine whether semaglutide is appropriate for their individual situation, given their full medical history and other medications.

How is semaglutide taken?

Injectable forms of semaglutide (Ozempic and injectable Wegovy) are given as subcutaneous (under-the-skin) injections once a week on the same day each week. Common injection sites include the abdomen, outer thigh, and upper arm. Both brands use prefilled auto-injector pens that do not require drawing medication from a vial. Dose-titration schedules start at a low dose and increase gradually over several months, allowing the body to adjust and reducing the intensity of early gastrointestinal side effects. For injectable Wegovy, the titration schedule typically takes 16 to 20 weeks to reach the 2.4 mg maintenance dose. Oral formulations (Rybelsus and oral Wegovy) require specific handling for adequate absorption: the tablet is taken on a completely empty stomach with no more than 4 ounces (120 ml) of plain water, and the person must wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Tablets must not be split, crushed, or chewed. All injection technique, site rotation, storage requirements (injectable semaglutide must be refrigerated until opened), missed-dose instructions, and travel guidance should come from the prescribing provider and the pharmacy's official Instructions for Use. The information in this article is an educational overview only and is not a substitute for individualized instruction from a licensed clinician or pharmacist.

What is compounded semaglutide and how does it differ from FDA-approved products?

Compounded semaglutide is prepared by a licensed compounding pharmacy, either a state-licensed 503A pharmacy filling individual patient prescriptions or an FDA-registered 503B outsourcing facility producing larger batches for healthcare providers. These pharmacies are entirely separate from the manufacturer of FDA-approved brand-name semaglutide products. Compounded semaglutide is not FDA-approved. The FDA does not evaluate compounded drugs for safety, efficacy, or quality before they are dispensed, and compounded versions have not been studied in the large, placebo-controlled trials that established the efficacy and safety profile of the approved brand-name formulations. Compounded semaglutide became widely available during a period when the FDA had listed semaglutide on the national drug shortage list, a legal window that permitted compounding under specific conditions. The FDA declared that shortage resolved in February 2025. In April 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, which would further restrict large-scale compounding of these drugs. The regulatory landscape is actively evolving; patients should consult a licensed provider and monitor current FDA guidance. For a detailed review of the safety evidence, see Is compounded semaglutide safe?

What are the most common side effects of semaglutide?

Gastrointestinal side effects are the most frequently reported reactions to semaglutide. Nausea affects a substantial portion of users, particularly during dose escalation; clinical trial data suggest it occurs in roughly 20 to 44 percent of people depending on formulation and dose, according to StatPearls. Vomiting, diarrhea, constipation, and stomach discomfort are also common early on. Most of these effects improve as the body adjusts to the medication. Eating smaller portions, avoiding high-fat or very rich foods, and staying well hydrated can help reduce nausea. Less common but more serious risks include acute pancreatitis, gallbladder disease (including gallstones), and, in people who already have diabetic eye disease, the possibility of a temporary worsening of diabetic retinopathy. Semaglutide carries a boxed warning about thyroid tumors observed in animal studies, which is why it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. A clinician reviewing a patient's complete medical history and current medicines will weigh these risks before prescribing. Anyone who experiences severe or persistent abdominal pain, signs of a serious allergic reaction, or other concerning symptoms while taking semaglutide should contact a healthcare provider promptly. Stopping semaglutide should always involve medical guidance; for what to expect if treatment ends, see What happens when you stop taking a GLP-1 medication?